The use of probiotics in depression

Klaus W. Lange*, Yukiko Nakamura and Katharina M. Lange

Department of Experimental Psychology, University of Regensburg, Germany

*Corresponding author: Klaus W. Lange, Institute of Psychology, University of Regensburg, 93040 Regensburg, Germany. Tel: +49 941 9433815; Fax: +49 941 9434496; E-mail: klaus.lange@ur.de

DOI: 10.31665/JFB.2020.1224

Received: December 14, 2020; Revised received & accepted: December 26, 2020


Abstract

Probiotics are thought to play a role in the extensive bidirectional communication between gut microbiota and the brain. A growing body of preclinical data suggests that probiotics may be effective in alleviating low mood and improving depressive symptoms. Preliminary evidence derived from studies in rodent models supports the view that single-strain or multi-strain preparations of Bifidobacterium and Lactobacillus are able to improve behaviors related to depression. The extent of antidepressant effects in humans with a clinical diagnosis of depression is less clear. While some support for the efficacy of probiotic supplementation has been found, the pooled effects in meta-analyses have generally been small. The positive effects reported for probiotics in major depression should be regarded as preliminary. Large, randomized trials assessing the efficacy of specific probiotic strain combinations over various time spans in individuals with clinically significant presentations of depression are needed to evaluate the therapeutic potential of probiotics. In light of accumulating evidence showing that probiotics may have beneficial effects in reducing depressive symptoms and may be useful as an adjunct intervention in major depressive disorder, the efficacy of probiotic foods in the prevention of depression should be investigated.

Keywords: Probiotics; Depression; Gut microbiome; Treatment; Prevention.

1. Introduction

Major depression is a common psychiatric disorder characterized by depressed mood or significantly reduced pleasure or interest in all activities (American Psychiatric Association, 2013). Major depressive disorder is highly debilitating, severely limiting psychosocial functioning and diminishing the quality of life of affected individuals (Malhi and Mann, 2018). The rate of recurrence is high and the treatment of depression poses a major challenge (Malhi and Mann, 2018). Up to 60% of individuals with major depressive disorder have been estimated to experience some degree of non-response to pharmacotherapy (Fava, 2003). Furthermore, major depression has been projected by the World Health Organization to rank as the first cause of global burden of disease by 2030 (World Health Organization, 2008). Subclinical levels of depressive symptoms can be observed in healthy populations (Gawlik et al., 2013).

Pharmacotherapy and psychotherapy are commonly used to treat people with depression. However, the ability of these treatment strategies to avert disease burden remains limited (e.g. Casacalenda et al., 2002). The need for the development of novel pharmacological compounds for depression has repeatedly been emphasized (e.g. Insel, 2015; Miller, 2010), and additional approaches in the prevention and treatment of depression are required. In view of this, nutritional psychiatry has developed as a new field of research, since diet quality and nutrition are important in the promotion of metabolic health (Bennett et al., 2015; Lange, 2017a; Lange, 2017b), and have also been shown to be involved in the regulation of mental health and to be modifiable risk factors for mental disorders (e.g. Lange, 2018a; Lange, 2020; Marx et al., 2017). For example, dietary patterns such as the Mediterranean diet, with limited amounts of processed foods and high consumption of fruit, vegetables, nuts, seeds, wholegrains and fish, have been found to be inversely correlated with the risk of depression (Lai et al., 2014; Opie et al., 2015; Psaltopoulou et al., 2013). In contrast, high-sugar and high-fat diets containing large amounts of processed foods (Western diets) appear to be positively associated with depression (Lai et al., 2014). A con-
2. Gut microbiota and brain function

The microbiota is a community of commensal, symbiotic and pathogenic microorganisms, the majority of which live in the gastrointestinal tract (Gill et al., 2006). The human intestine is colonized by bacteria, archaea and eukaryotes, the number of which may approximate the number of cells in the human body (Sender et al., 2016). Genetic, epigenetic and especially dietary factors can influence the intestinal microbiota (Yadav et al., 2018). While symbiosis of the intestinal microbiota can contribute to the maintenance of undisturbed physiological conditions in the host, dysbiosis, i.e. an imbalance in gut microbiota, may be involved in the pathogenesis of various diseases, such as cardiovascular, gastrointestinal and immune-related diseases (Gourbeyre et al., 2011; Hungin et al., 2013; Khaledi et al. 2014) as well as mental disorders (e.g. Lange et al., 2020, Mohajeri et al., 2018).

Emerging evidence suggests a bidirectional interaction between the microbial communities in the gastrointestinal tract and the host central nervous system via the gut-brain axis (Cryan and Dinan, 2012; Dinan and Cryan, 2017a; Foster and Neufeld, 2013). Preclinical studies in animal models have found links between changes or deficits of the intestinal microbiota and neurochemical alterations in the brain, and the gut microbiota has been demonstrated to influence brain development, central functions and behaviors of the host (Bercik et al., 2011a; Crumeyrolle-Arias et al., 2014; Cryan and Dinan, 2012; Desbonnet et al., 2014; Diaz Heijtz et al., 2011; Dinan and Cryan, 2017b; Rogers et al., 2016). For example, an early study in germ-free mice observed a link between the gut microbiota and a reduction in brain-derived neurotrophic factor concentrations in the hippocampus and an elevated stress response in the hypothalamic-pituitary-adrenal axis (Sudo et al., 2004).

Other findings in mice, showing marked differences in the volume and dendritic morphology of the hippocampus and amygdala and between germ-free mice and conventionally colonized mice (Luczynski et al., 2016), suggest that the gut microbiome plays a key role in the development of normal brain morphology and ultrastructure of central neurons. The hypothesis that the gut microbiota can modulate brain function and modify behavior is supported by preclinical studies of germ-free animals, bacterial infections, fecal transplantation and probiotic treatment (Cryan and Dinan, 2012). Furthermore, intestinal microbial dysbiosis could be implicated in neuropsychiatric disorders, such as depression, bipolar disorder, schizophrenia and autism spectrum disorders (Lange et al., 2020; Rogers et al., 2016). For example, individuals with major depressive disorder appear to have distinct compositions of the gut microbiota in comparison with healthy people (Jiang et al., 2015; Naseribafrouei et al., 2014). Further findings in support of a role of the intestinal microbiota in the modulation of depressive symptoms in humans are presented in Table 1. These observations support the view that the intestinal microbiota could be a potential target for novel antidepressant interventions.

3. Probiotics and depression

3.1. Animal studies

Probiotics are live microorganisms whose consumption contributes to the intestinal microbial flora of the host, resulting in beneficial health effects (World Health Organization, 2001). In respect to the central nervous system, a number of behavioral experiments investigating potentially positive effects of probiotics on brain and behavior have been conducted in rodents. For example, colonizing germ-free mice with Bifidobacterium infantis has been shown to normalize their previously overreactive hypothalamic-pituitary-adrenal axis in response to restraint stress and to decrease their stress hormone levels to those found in control animals (Sudo et al., 2004). Various mechanisms have been suggested to be involved in the effects of probiotics on brain functions, including the regulation of mood and emotion (see Table 2).

Most of the available animal studies have used single-strain or multi-strain preparations of Bifidobacterium (B. breve, B. longum, B. infantis) and Lactobacillus (L. casei, L. helveticus, L. plantarum, L. rhamnosus) and explored their effects on rodents in tests assessing depression-like behaviors, such as the forced-swim, tail-suspension and sucrose-preference tests. Based on the findings in animal models, all of these preparations have been shown to improve behaviors related to depression (for review see Wang et al., 2016). However, the heterogeneity of the studies in regard to factors such as probiotic strains, dose and duration of probiotic administration, rodent strains, health conditions of animals and brain and behavioral functions assessed needs to be considered. Moreover, findings in preclinical rodent models of depression cannot be directly translated to clinical interventions in individuals with depression.

3.2. Epidemiology

A nationwide, large cross-sectional study conducted in Korea, in-

---

Table 1. Experimental findings supporting a role of the gut microbiome in the modulation of depressive symptoms

| Development of depressive-like behaviors in germ-free mice inoculated with fecal samples of individuals with depression (Zheng et al., 2016) |
| Different composition of the intestinal microbiota of individuals with major depressive disorder compared to controls (Bravo et al., 2011; Jiang et al., 2015; Zheng et al., 2016) |
| Altered counts of both gram-positive and gram-negative bacteria in individuals with depression (Jiang et al., 2015; Naseribafrouei et al., 2014) |
| Link between alterations in the microbiome (e.g. Faecalibacterium) of individuals with depression and severity of depression (Jiang et al., 2015) |
In humans, various problems of the studies investigating the use of probiotics in depression need to be considered (see Table 4). Major limitations include small sample sizes, short durations of probiotic supplementation and the wide variety of single-strain and multiple-strain probiotics administered. The long-term efficacy of probiotics, in particular on the remission of depression, and lasting effects following discontinuation of their administration are unclear. Probiotic supplements appear to be well-tolerated, with low drop-out rates in the available studies (Nikolova et al., 2019). However, possible adverse events following extended use of probiotics are unknown.

In summary, our knowledge regarding the clinical effectiveness of probiotics in depression is insufficient. Therefore, further high-quality studies investigating their effects in major depressive disorder and determining optimal composition, dosage and duration of probiotic supplementation are warranted. It is noteworthy that in other fields of clinical medicine, such as the management of gastrointestinal disorders, the accumulation of evidence has often weakened rather than strengthened the case for the therapeutic use of probiotics (Preidis et al., 2020).

The mechanisms involved in the effects of probiotics on depression, in particular those related to stress, should be explored in more detail. A recent systematic review and meta-analysis, based on randomized controlled trials of the effects of probiotics on stress in healthy people, concluded that probiotics can decrease subjective stress levels in healthy individuals and could alleviate stress-related subthreshold levels of depression and anxiety (Zhang et al., 2020). Most animal models used for the assessment of the effects of probiotics on behaviors related to depression cannot, for ethical reasons, be adapted to humans. However, future investigations may correlate gut microbiota composition with specific behaviors and manipulate the interaction between gut microbiota and central nervous system using probiotics.

The epidemiological findings from Korea, demonstrating a positive influence of the consumption of probiotic foods on depression (Kim and Shin, 2019), point to a preventive potential of probiotics. Such benefits would probably require an intake of probiotics over extended periods of time. A recommendation for consumption of probiotics may be made in view of the apparent lack of adverse events associated with their intake. However, scientific evaluation of this approach will be limited to observations, since a high-quality randomized study design is not feasible. Furthermore, self-treatment with dietary supplements without proven benefit is not recommended.

An important, though frequently neglected factor in the assessment of food bioactives in mental disorders is related to etiology and psychopathology. Biological, environmental, social and cultural factors are involved in the etiology of depression, and the diagnosis of depression relies on a number of symptoms, none of which are pathognomonic of the condition (Malhi and Mann, 2018).

### 3.3. Clinical trials

In recent years, several systematic reviews and meta-analyses have analyzed the effects of probiotics on depression (see Table 3). Many of the randomized controlled trials conducted in this area have assessed the impact of probiotics on (subclinical) depressive symptoms in healthy people. The results of these trials, however, cannot be extrapolated to people with clinically diagnosed depression. Studies investigating supplementary probiotic interventions in the treatment of individuals with a clinical diagnosis of depression have recently been systematically reviewed (Nikolova et al., 2019). All studies included in the review demonstrated significant improvements in one or more outcome measures of the impact of probiotics in comparison with placebo or no-treatment conditions or with assessments at baseline (Nikolova et al., 2019). No negative effects or adverse events related to the use of probiotics were reported. However, this could reflect positive reporting bias, since systematic reporting of adverse events associated with probiotic interventions appears to be lacking (Gwec et al., 2018). Most of the studies were conducted in individuals with depression who were receiving antidepressant medication. Probiotics should therefore be considered as complementary to standard therapy rather than as an alternative. Taken together, the findings suggest that the administration of probiotics may be useful as an add-on treatment in clinical depression.

### 4. Future directions

In view of the evidence from the available findings of both animal and human studies, probiotics appear to be capable of improving brain function and depressive symptomatology (Wang et al., 2016). The results of preclinical experiments suggesting antidepressant efficacy of probiotics cannot be directly translated to clinical trials. In humans, various problems of the studies investigating the use of probiotics in depression need to be considered (see Table 4). Major limitations include small sample sizes, short durations of probiotic supplementation and the wide variety of single-strain and multiple-strain probiotics administered. The long-term efficacy of probiotics, in particular on the remission of depression, and lasting effects following discontinuation of their administration are unclear. Probiotic supplements appear to be well-tolerated, with low drop-out rates in the available studies (Nikolova et al., 2019). However, possible adverse events following extended use of probiotics are unknown.

In summary, our knowledge regarding the clinical effectiveness of probiotics in depression is insufficient. Therefore, further high-quality studies investigating their effects in major depressive disorder and determining optimal composition, dosage and duration of probiotic supplementation are warranted. It is noteworthy that in other fields of clinical medicine, such as the management of gastrointestinal disorders, the accumulation of evidence has often weakened rather than strengthened the case for the therapeutic use of probiotics (Preidis et al., 2020).

The mechanisms involved in the effects of probiotics on depression, in particular those related to stress, should be explored in more detail. A recent systematic review and meta-analysis, based on randomized controlled trials of the effects of probiotics on stress in healthy people, concluded that probiotics can decrease subjective stress levels in healthy individuals and could alleviate stress-related subthreshold levels of depression and anxiety (Zhang et al., 2020). Most animal models used for the assessment of the effects of probiotics on behaviors related to depression cannot, for ethical reasons, be adapted to humans. However, future investigations may correlate gut microbiota composition with specific behaviors and manipulate the interaction between gut microbiota and central nervous system using probiotics.

The epidemiological findings from Korea, demonstrating a positive influence of the consumption of probiotic foods on depression (Kim and Shin, 2019), point to a preventive potential of probiotics. Such benefits would probably require an intake of probiotics over extended periods of time. A recommendation for consumption of probiotics may be made in view of the apparent lack of adverse events associated with their intake. However, scientific evaluation of this approach will be limited to observations, since a high-quality randomized study design is not feasible. Furthermore, self-treatment with dietary supplements without proven benefit is not recommended.

An important, though frequently neglected factor in the assessment of food bioactives in mental disorders is related to etiology and psychopathology. Biological, environmental, social and cultural factors are involved in the etiology of depression, and the diagnosis of depression relies on a number of symptoms, none of which are pathognomonic of the condition (Malhi and Mann, 2018).
In short, depression is a clinically and probably pathophysiologically heterogeneous condition. Thus, as in other mental disorders, there is unlikely to be a one-fits-all solution in regard to the therapeutic efficacy of food bioactives such as probiotics (Lange, 2018b; Lange et al. 2020). The identification of subgroups of people who are most likely to benefit from probiotic supplementation may therefore be necessary.

5. Conclusion

Novel treatments are needed to reduce the global burden of ma-

### Table 4. Limitations and problems of the available findings in respect to the use of probiotics in depression

<table>
<thead>
<tr>
<th>Limitations and problems</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-report of depressive symptoms versus clinically confirmed diagnosis of major depressive disorder.</td>
</tr>
<tr>
<td>Threshold of depression severity for inclusion (mild versus moderate).</td>
</tr>
<tr>
<td>Small sample sizes in studies of individuals with major depressive disorder.</td>
</tr>
<tr>
<td>Wide variety of composition of the single-strain and multiple-strain probiotics used.</td>
</tr>
<tr>
<td>Dose and duration of probiotic supplementation.</td>
</tr>
<tr>
<td>Use of probiotics as supplementation to pharmacological therapy or as sole treatment.</td>
</tr>
<tr>
<td>Degree of improved symptomatology: symptom rating scales versus remission of depression.</td>
</tr>
<tr>
<td>Different antidepressive effects of probiotics in different age groups.</td>
</tr>
<tr>
<td>Unclear long-term efficacy of probiotics during supplementation and following discontinuation.</td>
</tr>
</tbody>
</table>
ior depression. The use of probiotics in depression has attracted increasing scientific and clinical interest in recent years. Both preclinical and clinical findings suggest that targeting the gut-microbiota-brain axis using probiotics may be a useful approach in reducing the severity of depression. The available evidence suggests that the role of intestinal microbiota and the use of probiotics in both the treatment and prevention of depression deserves more intensive investigation. However, the current evidence for probiotics in the therapy of major depression is modest. While some support for their efficacy has been found, the pooled effects in meta-analyses were generally small. Therefore, the positive effects observed for probiotics in major depression need to be regarded as preliminary. Large, randomized trials assessing the efficacy of specific probiotic strain combinations over various time spans in individuals with clinically significant presentations of depression are needed in order to evaluate the therapeutic potential of probiotics. In addition, the mechanisms underlying the probiotic effects on depression should be further elucidated.

References


